Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 4 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| South Korea Pharmaceutical Market Outlook 2013 Overview | 10 | 19 |
| Global Pharmaceutical Industry Landscape | 10 | 1 |
| Macroscopic View of the South Korea Pharmaceutical Market | 10 | 2 |
| Trade Balance | 12 | 1 |
| Exports | 13 | 3 |
| Imports | 16 | 2 |
| Demographic Analysis | 18 | 1 |
| Population Size, Growth, and Structure | 18 | 1 |
| Crude Death Rate | 19 | 1 |
| Causes of Death | 20 | 2 |
| Crude Birth Rate | 22 | 1 |
| Infant Mortality Rate | 23 | 1 |
| Life Expectancy at Birth | 24 | 1 |
| Comparison of Healthcare Indicators | 25 | 1 |
| Driver and Barriers of South Korean Pharmaceutical Industry | 26 | 1 |
| Drivers | 26 | 1 |
| Rapidly Aging Population | 26 | 1 |
| Supportive Government Policies and Investments | 26 | 1 |
| Conducive Environment for Clinical Trials | 27 | 1 |
| Insurance Coverage of the Entire Population | 27 | 1 |
| Barriers | 28 | 1 |
| Government s Limitations on Drug Reimbursements | 28 | 1 |
| Revised Pricing Measures | 28 | 1 |
| FTAs Effect on Domestic Companies | 28 | 1 |
| South Korea Pharmaceutical Market Outlook 2013 Industry Characteristics | 29 | 12 |
| Regulatory Agencies | 29 | 1 |
| Korea Food and Drug Administration | 29 | 1 |
| National Institute of Food and Drug Safety Evaluation | 30 | 1 |
| Drug Pricing Policy | 31 | 1 |
| Healthcare Expenditure in South Korea | 32 | 5 |
| Healthcare Infrastructure | 37 | 1 |
| Insurance and Reimbursement | 38 | 1 |
| National Health Insurance | 38 | 1 |
| Long-term Care Insurance | 39 | 1 |
| Medical Aid | 40 | 1 |
| South Korea Pharmaceutical Market Outlook 2013 Market Analysis | 41 | 7 |
| Over-the-Counter drugs | 41 | 1 |
| Prescription Drugs | 42 | 1 |
| Patented Drugs | 43 | 1 |
| Generics | 44 | 1 |
| Biotechnology | 45 | 3 |
| South Korea Pharmaceutical Market Outlook 2013 Key Trends | 48 | 7 |
| Rapid Consolidations in the Domestic Market | 48 | 1 |
| M&A deals | 48 | 2 |
| Partnership Deals | 50 | 1 |
| Licensing Deals | 51 | 1 |
| Understanding Local Markets to Build R&D | 52 | 1 |
| Free Trade Agreements | 53 | 1 |
| Intellectual Property Rights Protection | 54 | 1 |
| Transparency in Healthcare Regulatory and Reimbursement Process | 54 | 1 |
| Unethical Business Practices | 54 | 1 |
| South Korea Pharmaceutical Market Outlook 2013 Competitive Landscape | 55 | 6 |
| Key Foreign Companies | 55 | 1 |
| GlaxoSmithKline | 55 | 1 |
| Sanofi | 55 | 1 |
| Pfizer | 56 | 1 |
| Key Domestic Companies | 57 | 1 |
| Dong-A | 57 | 1 |
| Green Cross | 58 | 1 |
| Hanmi | 59 | 1 |
| JW Holdings Corporation (Choongwae Holdings Co., Ltd.) | 60 | 1 |
| Yuhan Corporation | 60 | 1 |
| South Korea Pharmaceutical Market Outlook 2013 The Way Forward | 61 | 2 |
| Outlook | 61 | 1 |
| Opportunities Ahead | 61 | 1 |
| Biosimilars | 61 | 1 |
| Stem Cell Research | 61 | 2 |
| South Korea Pharmaceutical Market Outlook 2013 Appendix | 63 | 5 |
| Market Definitions | 63 | 1 |
| Abbreviations | 63 | 1 |
| Bibliography | 64 | 2 |
| Research Methodology | 66 | 2 |
| Coverage | 66 | 1 |
| Secondary Research | 66 | 1 |
| Primary Research | 66 | 1 |
| Expert Panel Validation | 67 | 1 |
| Contact Us | 67 | 1 |
| Disclaimer | 67 | 1 |